Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning

Critical Reviews in Oncology/Hematology

Volumn 105, Issue , 2016, Pages 73-83

  Gadducci, Angiolo ^a   Biglia, Nicoletta ^b   Tana, Roberta ^a   Cosio, Stefania ^a   Gallo, Martina ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

AMP activated protein kinase AMPK ; Breast cancer; Chemoprevention; Diabetes; Endometrial cancer; Insulin; Insulin like growth factor IGF ; Mammalian target of rapamycin mTOR ; Metformin; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MEDROXYPROGESTERONE ACETATE; METFORMIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CANCER PREVENTION; DIABETES MELLITUS; DRUG REPOSITIONING; DRUG USE; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE GENITAL TRACT CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; OVARIAN CANCER CELL LINE; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BREAST NEOPLASMS; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; FEMALE; OVARIAN NEOPLASMS;

ANIMALS; BREAST NEOPLASMS; DRUG REPOSITIONING; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; METFORMIN; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85003758669     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.06.006     Document Type: Review

References (139)

1. Alimova, I.N., Liu, B., Fan, Z., Edgerton, S.M., Dillon, T., Lind, S.E., Thor, A.D., Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8 (2009), 909–915.
2. Alison, M.R., Lin, W.R., Lim, S.M., Nicholson, L.J., Cancer stem cells: in the line of fire. Cancer Treat. Rev. 38 (2012), 589–598.
3. Bakhru, A., Buckanovich, R.J., Griggs, J.J., The impact of diabetes on survival in women with ovarian cancer. Gynecol. Oncol. 121 (2011), 106–111.
4. Banno, K., Iida, M., Yanokura, M., Irie, H., Masuda, K., Kobayashi, Y., Tominaga, E., Aoki, D., Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer. Sci. World J., 2015, 2015, 341362.
5. Bao, B., Azmi, A.S., Ali, S., Zaiem, F., Sarkar, F.H., Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. Ann. Transl. Med., 2, 2014, 59.
6. Bayraktar, S., Hernadez-Aya, L.F., Lei, X., Meric-Bernstam, F., Litton, J.K., Hsu, L., Hortobagyi, G.N., Gonzalez-Angulo, A.M., Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118 (2012), 1202–1211.
7. Becker, C., Jick, S.S., Meier, C.R., Bodmer, M., Metformin and the risk of endometrial cancer: a case-control analysis. Gynecol. Oncol. 129 (2013), 565–569.
8. Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.F., Bost, F., Metformin in cancer therapy: a new perspective for an old antidiabetic drug. Mol. Cancer Ther. 9 (2010), 1092–1099.
9. Bodmer, M., Meier, C., Krähenbühl, S., Jick, S.S., Meier, C.R., Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33 (2010), 1304–1308.
10. Bodmer, M., Becker, C., Meier, C., Jick, S.S., Meier, C.R., Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol. Oncol. 123 (2011), 200–204.
11. Bosco, J.L., Antonsen, S., Sørensen, H.T., Pedersen, L., Lash, T.L., Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol. Biomarkers Prev. 20 (2011), 101–111.
12. Bowker, S., Majumdar, S., Veugelers, P., Johnson, J.A., Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 5 (2006), 254–258.
13. Boyle, P., Boniol, M., Koechlin, A., Robertson, C., Valentini, F., Coppens, K., Fairley, L.L., Boniol, M., Zheng, T., Zhang, Y., Pasterk, M., Smans, M., Curado, M.P., Mullie, P., Gandini, S., Bota, M., Bolli, G.B., Rosenstock, J., Autier, P., Diabetes and breast cancer risk: a meta-analysis. Br. J. Cancer 107 (2012), 1608–1617.
14. Brown, K.A., Samarajeewa, N.U., Simpson, E.R., Endocrine-related cancers and the role of AMPK. Mol. Cell. Endocrinol. 366 (2013), 170–179.
15. Buac, D., Kona, F.R., Seth, A.K., Dou, Q.P., Regulation of metformin response by breast cancer associated gene 2. Neoplasia 15 (2013), 1379–1390.
16. Calle, E.E., Rodriguez, C., Walker-Thurmond, K., Thun, M.J., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348 (2003), 1625–1638.
17. Campagnoli, C., Pasanisi, P., Abbà C., Ambroggio, S., Biglia, N., Brucato, T., Colombero, R., Danese, S., Donadio, M., Venturelli, E., Zito, G., Berrino, F., Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin. Breast Cancer 12 (2012), 175–182.
18. Campagnoli, C., Berrino, F., Venturelli, E., Abbà C., Biglia, N., Brucato, T., Cogliati, P., Danese, S., Donadio, M., Zito, G., Pasanisi, P., Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. Clin. Breast Cancer 13 (2013), 433–438.
19. Cantrell, L.A., Zhou, C., Mendivil, A., Malloy, K.M., Gehrig, P.A., Bae-Jump, V.L., Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategy. Gynecol. Oncol. 5 (2010), 92–98.
20. Carvajal, R., Rosas, C., Kohan, K., Gabler, F., Vantman, D., Romero, C., Vega, M., Metformin augments the levels of molecules that regulate the expression of the insulin-dependent glucose transporter GLUT4 in the endometria of hyperinsulinemic PCOS patients. Hum. Reprod. 28 (2013), 2235–2244.
21. Chlebowski, R.T., McTiernan, A., Wactawski-Wende, J., Manson, J.E., Aragaki, A.K., Rohan, T., Ipp, E., Kaklamani, V.G., Vitolins, M., Wallace, R., Gunter, M., Phillips, L.S., Strickler, H., Margolis, K., Euhus, D.M., Diabetes, metformin, and breast cancer in postmenopausal women. J. Clin. Oncol. 30 (2012), 2844–2852.
22. Cornejo, K.M., Kandil, D., Khan, A., Cosar, E.F., Theranostic and molecular classification of breast cancer. Arch. Pathol. Lab. Med. 138 (2014), 44–56.
23. Currie, C.J., Poole, C.D., Gale, E.A., The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52 (2009), 1766–1777.
24. De Bruijn, K.M., Arends, L.R., Hansen, B.E., Leeflang, S., Ruiter, R., van Eijck, C.H., Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br. J. Surg. 100 (2013), 1421–1429.
25. DeCensi, A., Puntoni, M., Guerrieri-Gonzaga, A., Cazzaniga, M., Serrano, D., Lazzeroni, M., Vingiani, A., Gentilini, O., Petrera, M., Viale, G., Cuzick, J., Bonanni, B., Pruneri, G., Effect of metformin on breast ductal carcinoma in situ proliferation in a randomized presurgical trial. Cancer Prev. Res. (Phila.) 8 (2015), 888–894.
26. Decensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., Gandini, S., Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev. Res. (Phila.) 3 (2010), 1451–1461.
27. Del Barco, S., Vazquez-Martin, A., Cufi, S., Oliveras-Ferraros, C., Bosch-Barrera, J., Joven, J., Martin-Castillo, B., Menendez, J.A., Metformin: multi-faceted protection against cancer. Oncotarget 2 (2011), 896–917.
28. Deng, X.S., Wang, S., Deng, A., Liu, B., Edgerton, S.M., Lind, S.E., Wahdan-Alaswad, R., Thor, A.D., Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 11 (2012), 367–376.
29. Deng, D., Yang, Y., Tang, X., Skrip, L., Qiu, J., Wang, Y., Zhang, F., Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis. Diabetes Metab. Res. Rev. 31 (2015), 595–602.
30. Dilokthornsakul, P., Chaiyakunapruk, N., Termrungruanglert, W., Pratoomsoot, C., Saokeaw, S., Sruamsiri, R., The effects of metformin on ovarian cancer: a systematic review. Int. J. Gynecol. Cancer 23 (2013), 1544–1551.
31. Dong, L., Zhou, Q., Zhang, Z., Zhu, Y., Duan, T., Feng, Y., Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. J. Obstet. Gynaecol. Res. 38 (2012), 1077–1085.
32. Dowling, R.J., Zakikhani, M., Fantus, I.G., Pollak, M., Sonenberg, N., Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67 (2007), 10804–10812.
33. Dumesic, D.A., Lobo, R.A., Cancer risk and PCOS. Steroids 8 (2013), 782–785.
34. Dunlop, M.G., Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut 51:Suppl. 5 (2002), v21–v27.
35. El-Mir, M.Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., Leverve, X., Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275 (2000), 223–228.
36. Engelman, J.A., Cantley, L.C., Chemoprevention meets glucose control. Cancer Prev. Res. (Phila.) 3 (2010), 1049–1052.
37. Erices, R., Bravo, M.L., Gonzalez, P., Oliva, B., Racordon, D., Garrido, M., Ibañez, C., Kato, S., Brañes, J., Pizarro, J., Barriga, M.I., Barra, A., Bravo, E., Alonso, C., Bustamente, E., Cuello, M.A., Owen, G.I., Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells. Reprod. Sci. 20 (2013), 1433–1446.
38. Ersoy, C., Kiyici, S., Budak, F., Oral, B., Guclu, M., Duran, C., Selimoglu, H., Erturk, E., Tuncel, E., Imamoglu, S., The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res. Clin. Pract. 81 (2008), 56–60.
39. Evans, J.M., Donnelly, L.A., Emslie-Smith, A.M., Alessi, D.R., Morris, A.D., Metformin and reduced risk of cancer in diabetic patients. Br. Med. J. 330 (2005), 1304–1305.
40. Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G.F., Pellegrini, F., Nicolucci, A., Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One, 8, 2013, e71583.
41. Gadducci, A., Genazzani, A.R., Steroid hormones in endometrial and breast cancer. Review. Eur. J. Gynaecol. Oncol. 18 (1997), 371–378.
42. Gadducci, A., Cosio, S., Genazzani, A.R., Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. Crit. Rev. Oncol. Hematol. 80 (2011), 181–192.
43. Gallagher, E.J., LeRoith, D., Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann. N. Y. Acad. Sci. 1243 (2011), 54–68.
44. Goodwin, P.J., Ennis, M., Pritchard, K.I., Trudeau, M.E., Koo, J., Madarnas, Y., Hartwick, W., Hoffman, B., Hood, N., Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol. 20 (2002), 42–51.
45. Gotlieb, W.H., Saumet, J., Beauchamp, M.C., Gu, J., Lau, S., Pollak, M.N., Bruchim, I., In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol. Oncol. 110 (2008), 246–250.
46. Hanna, R.K., Zhou, C., Malloy, K.M., Sun, L., Zhong, Y., Gehrig, P.A., Bae-Jump, V.L., Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol. Oncol. 125 (2012), 458–469.
47. Hardefeldt, P.J., Edirimanne, S., Eslick, G.D., Diabetes increases the risk of breast cancer: a meta-analysis. Endocr. Relat. Cancer 19 (2012), 793–803.
48. Hardie, D.G., AMP-activated protein kinase as a drug target. Annu. Rev. Pharmacol. Toxicol. 47 (2007), 185–210.
49. Hardie, D.G., AMPKα.key regulator of energy balance in the single cell and the whole organism. Int. J. Obes. 32:Suppl. 4 (2008), S7–S12.
50. Hatoum, D., McGowan, E.M., Recent advances in the use of metformin: can treating diabetes prevent breast cancer?. Biomed. Res. Int., 2015, 2015, 548436.
51. Hawkes, A.L., Quinn, M., Gebski, V., Armes, J., Brennan, D., Janda, M., feMME Trial Committee, Obermair, A., Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial. Contemp. Clin. Trials 39 (2014), 14–21.
52. He, X., Esteva, F.J., Ensor, J., Hortobagyi, G.N., Lee, M.H., Yeung, S.C., Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann. Oncol. 23 (2012), 1771–1780.
53. Hirsch, H.A., Iliopoulos, D., Tsichlis, P.N., Struhl, K., Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69 (2009), 7507–7511.
54. Huang, N.-L., Chiang, S.-H., Hsueh, C.-H., Liang, Y.-J., Chen, Y.-J., Lai, L.-P., Metformin inhibits TNF-α-induced IκB kinase phosphorylation, IκB-α degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Int. Cardiol. 134 (2009), 169–175.
55. Hwang, I.C., Park, S.M., Shin, D., Ahn, H.Y., Rieken, M., Shariat, S.F., Metformin association with lower prostate cancer recurrence in type 2 diabetes: a systematic review and meta-analysis. Asian Pac. J. Cancer Prev. 16 (2015), 595–600.
56. Iglesias, D.A., Yates, M.S., van der Hoeven, D., Rodkey, T.L., Zhang, Q., Co, N.N., Burzawa, J., Chigurupati, S., Celestino, J., Bowser, J., Broaddus, R., Hancock, J.F., Schmandt, R., Lu, K.H., Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol. Cancer Ther. 12 (2013), 2847–2856.
57. Iliopoulos, D., Hirsch, H.A., Struhl, K., Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 71 (2011), 3196–3201.
58. Jalving, M., Gietema, J.A., Lefrandt, J.D., de Jong, S., Reyners, A.K., Gans, R.O., de Vries, E.G., Metformin: taking away the candy for cancer. Eur. J. Cancer 46 (2010), 2369–2380.
59. Johnson, N.P., Metformin use in women with polycystic ovary syndrome. Ann. Transl. Med., 2, 2014, 56.
60. Kalogera, E., Dowdy, S.C., Bakkum-Gamez, J.N., Preserving fertility in young patients with endometrial cancer: current perspectives. Int. J. Womens Health 6 (2014), 691–701.
61. Kiderlen, M., de Glas, N.A., Bastiaannet, E., Engels, C.C., van de Water, W., de Craen, A.J., Portielje, J.E., van de Velde, C.J., Liefers, G.J., Diabetes in relation to breast cancer relapse and all-cause mortality in elderly breast cancer patients: a FOCUS study analysis. Ann. Oncol. 24 (2013), 3011–3016.
62. Kleinman, D., Karas, M., Roberts, C.T. Jr., LeRoith, D., Phillip, M., Segev, Y., Levy, J., Sharoni, Y., Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol. Endocrinology 5 (1995), 2531–2537.
63. Ko, E.M., Walter, P., Jackson, A., Clark, L., Franasiak, J., Bolac, C., Havrilesky, L.J., Secord, A.A., Moore, D.T., Gehrig, P.A., Bae-Jump, V., Metformin is associated with improved survival in endometrial cancer. Gynecol. Oncol. 132 (2014), 438–442.
64. Ko, E.M., Stürmer, T., Hong, J.L., Castillo, W.C., Bae-Jump, V., Funk, M.J., Metformin and the risk of endometrial cancer: a population-based cohort study. Gynecol. Oncol. 136 (2015), 341–347.
65. Komurov, K., Tseng, J.T., Muller, M., Seviour, E.G., Moss, T.J., Yang, L., Nagrath, D., Ram, P.T., The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol. Syst. Biol., 8, 2012, 596.
66. Kumar, S., Meuter, A., Thapa, P., Langstraat, C., Giri, S., Chien, J., Rattan, R., Cliby, W., Shridhar, V., Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer 119 (2013), 555–562.
67. Kwon, M.J., Shin, Y.K., Regulation of ovarian cancer stem cells or tumor-initiating cells. Int. J. Mol. Sci. 14 (2013), 6624–6648.
68. Laskov, I., Drudi, L., Beauchamp, M.C., Yasmeen, A., Ferenczy, A., Pollak, M., Gotlieb, W.H., Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol. Oncol. 134 (2014), 607–614.
69. Lathi, R.B., Hess, A.P., Tulac, S., Nayak, N.R., Conti, M., Giudice, L.C., Dose-dependent insulin regulation of insulin-like growth factor binding protein-1 in human endometrial stromal cells is mediated by distinct signaling pathways. J. Clin. Endocrinol. Metab. 90 (2005), 1599–1606.
70. Lee, J.-Y., Jeon, I., Kim, J.W., Song, Y.-S., Yoon, J.-M., Park, S.M., Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies. Int. J. Gynecol. Cancer 23 (2013), 402–412.
71. Lee, H., Park, H.J., Park, C.S., Oh, E.T., Choi, B.H., Williams, B., Lee, C.K., Song, C.W., Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined. PLoS One, 9, 2014, e87979.
72. Lega, I.C., Austin, P.C., Gruneir, A., Goodwin, P.J., Rochon, P.A., Lipscombe, L.L., Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 36 (2013), 3018–3026.
73. Lehmann, B.D., Bauer, J.A., Chen, X., Sanders, M.E., Chakravarthy, A.B., Shyr, Y., Pietenpol, J.A., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121 (2011), 2750–2767.
74. Lengyel, E., Litchfield, L.M., Mitra, A.K., Nieman, K.M., Mukherjee, A., Zhang, Y., Johnson, A., Bradaric, M., Lee, W., Romero, I.L., Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am. J. Obstet. Gynecol., 212, 2015, 479 e1-479. e10.
75. Li, X., Guo, Y.R., Lin, J.F., Feng, Y., Billig, H., Shao, R., Combination of Diane-35 and metformin to treat early endometrial carcinoma in PCOS women with insulin resistance. J. Cancer 5 (2014), 173–181.
76. Liao, C., Zhang, D., Mungo, C., Tompkins, D.A., Zeidan, A.M., Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecol. Oncol. 135 (2014), 163–171.
77. Liu, B., Fan, Z., Edgerton, S.M., Deng, X.S., Alimova, I.N., Lind, S.E., Thor, A.D., Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8 (2009), 2031–2040.
78. Liu, W., Monahan, K.B., Pfefferle, A.D., Shimamura, T., Sorrentino, J., Chan, K.T., Roadcap, D.W., Ollila, D.W., Thomas, N.E., Castrillon, D.H., Miller, C.R., Perou, C.M., Wong, K.K., Bear, J.E., Sharpless, N.E., LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 21 (2012), 751–764.
79. Liu, H., Scholz, C., Zang, C., Schefe, J.H., Habbel, P., Regierer, A.C., Schulz, C.O., Possinger, K., Eucker, J., Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res. 32 (2012), 1627–1637.
80. Luo, J., Beresford, S., Chen, C., Chlebowski, R., Garcia, L., Kuller, L., Regier, M., Wactawski-Wende, J., Margolis, K.L., Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br. J. Cancer 111 (2014), 1432–1439.
81. Ma, I., Allan, A.L., The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev. 7 (2011), 292–306.
82. Ma, J., Guo, Y., Chen, S., Zhong, C., Xue, Y., Zhang, Y., Lai, X., Wei, Y., Yu, S., Zhang, J., Liu, W., Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. BMC Cancer, 14, 2014, 172.
83. Maessen, D.E., Stehouwer, C.D., Schalkwijk, C.G., The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases. Clin. Sci. 128 (2015), 839–861.
84. Markowska, A., Pawałowska, M., Filas, V., Korski, K., Gryboś M., Sajdak, S., Olejek, A., Bednarek, W., Spiewankiewicz, B., Lubin, J., Markowska, J., Does Metformin affect ER, PR, IGF-1R, β-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer?. Diabetol. Metab. Syndr., 5, 2013, 76.
85. McCampbell, A.S., Broaddus, R.R., Loose, D.S., Davies, P.J., Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin. Cancer Res. 12 (2006), 6373–6378.
86. Mitsuhashi, A., Kiyokawa, T., Sato, Y., Shozu, M., Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer 120 (2014), 2986–2995.
87. Nevadunsky, N.S., Van Arsdale, A., Strickler, H.D., Moadel, A., Kaur, G., Frimer, M., Conroy, E., Goldberg, G.L., Einstein, M.H., Metformin use and endometrial cancer survival. Gynecol. Oncol. 132 (2014), 236–240.
88. Noto, H., Tsujimoto, T., Sasazuki, T., Noda, M., Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocr. Pract. 17 (2011), 616–628.
89. Noto, H., Goto, A., Tsujimoto, T., Noda, M., Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One, 7, 2012, e3341.
90. Oda, K., Stokoe, D., Taketani, Y., McCormick, F., High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65 (2005), 10669–10673.
91. Oppong, B.A., Pharmer, L.A., Oskar, S., Eaton, A., Stempel, M., Patil, S., King, T.A., The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Med. 3 (2014), 1025–1034.
92. Peairs, K.S., Barone, B.B., Snyder, C.F., Yeh, H.C., Stein, K.B., Derr, R.L., Brancati, F.L., Wolff, A.C., Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J. Clin. Oncol. 29 (2011), 40–46.
93. Qu, C., Zhang, W., Zheng, G., Zhang, Z., Yin, J., He, Z., Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. Mol. Cell. Biochem. 386 (2014), 63–71.
94. Rattan, R., Giri, S., Hartmann, L.C., Shridhar, V., Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J. Cell. Mol. Med. 15 (2011), 166–178.
95. Rattan, R., Graham, R.P., Maguire, J.L., Giri, S., Shridhar, V., Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 13 (2011), 483–491.
96. Richer, A.L., Friel, J.M., Carson, V.M., Inge, L.J., Whitsett, T.G., Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmgenomics Pers. Med. 8 (2015), 63–79.
97. Romero, I.L., McCormick, A., McEwen, K.A., Park, S., Karrison, T., Yamada, S.D., Pannain, S., Lengyel, E., Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemo-sensitivity. Obstet. Gynecol. 119 (2012), 61–67.
98. Sachdev, D., Yee, D., Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther. 6 (2007), 1–12.
99. Sakamoto, H., Mashima, T., Kizaki, A., Dan, S., Hashimoto, Y., Naito, M., Tsuruo, T., Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 95 (2000), 3214–3218.
100. Sakamoto, H., Mashima, T., Sato, S., Hashimoto, Y., Yamori, T., Tsuruo, T., Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin. Cancer Res. 7 (2001), 2513–2518.
101. Sarfstein, R., Friedman, Y., Attias-Geva, Z., Fishman, A., Bruchim, I., Werner, H., Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One, 8, 2013, e61537.
102. Schuler, K.M., Rambally, B.S., DiFurio, M.J., Sampey, B.P., Gehrig, P.A., Makowski, L., Bae-Jump, V.L., Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med. 4 (2015), 161–173.
103. Session, D.R., Kalli, K.R., Tummon, I.S., Damario, M.A., Dumesic, D.A., Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. Gynecol. Endocrinol. 17 (2003), 405–407.
104. Shafiee, M.N., Khan, G., Ariffin, R., Abu, J., Chapman, C., Deen, S., Nunns, D., Barrett, D.A., Seedhouse, C., Atiomo, W., Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help?. Gynecol. Oncol. 132 (2014), 248–253.
105. Shank, J.J., Yang, K., Ghannam, J., Cabrera, L., Johnston, C.J., Reynolds, R.K., Buckanovich, R.J., Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol. Oncol. 127 (2012), 390–397.
106. Shao, R., Li, X., Feng, Y., Lin, J.F., Billig, H., Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. J. Exp. Clin. Cancer Res., 33, 2014, 41.
107. Shen, Z.Q., Zhu, H.T., Lin, J.F., Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet. Gynecol. 112 (2008), 465–467.
108. Sivalingam, V.N., Myers, J., Nicholas, S., Balen, A.H., Crosbie, E.J., Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications. Hum. Reprod. Update 20 (2014), 853–868.
109. Soffer, D., Shi, J., Chung, J., Schottinger, J.E., Wallner, L.P., Chlebowski, R.T., Lentz, S.E., Haque, R., Metformin and breast and gynecological cancer risk among women with diabetes. BMJ Open Diabetes Res. Care, 3, 2015, e000049.
110. Stine, J.E., Bae-Jump, V., Metformin and gynecologic cancers. Obstet. Gynecol. Surv. 69 (2014), 477–489.
111. Tabrizi, A.D., Melli, M.S., Foroughi, M., Ghojazadeh, M., Bidadi, S., Antiproliferative effect of metformin on the endometrium—a clinical trial. Asian Pac. J. Cancer Prev. 15 (2014), 10067–10070.
112. Tebbe, C., Chhina, J., Dar, S.A., Sarigiannis, K., Giri, S., Munkarah, A.R., Rattan, R., Metformin limits the adipocyte tumor-promoting effect on ovarian cancer. Oncotarget 5 (2014), 4746–4764.
113. Tseng, C.H., Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan. Gynecol. Oncol. 138 (2015), 147–153.
114. Umene, K., Banno, K., Kisu, I., Yanokura, M., Nogami, Y., Tsuji, K., Masuda, K., Ueki, A., Kobayashi, Y., Yamagami, W., Tominaga, E., Susumu, N., Aoki, D., New candidate therapeutic agents for endometrial cancer: potential for clinical practice (review). Oncol. Rep. 29 (2013), 855–860.
115. Velasco, A., Bussaglia, E., Pallares, J., Dolcet, X., Llobet, D., Encinas, M., Llecha, N., Palacios, J., Prat, J., Matias-Guiu, X., PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum. Pathol. 37 (2006), 1465–1472.
116. Viollet, B., Guigas, B., Sanz Garcia, N., Leclerc, J., Foretz, M., Andreelli, F., Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. (Lond.) 122 (2012), 253–270.
117. Wang, C.F., Zhang, G., Zhao, L.J., Qi, W.J., Li, X.P., Wang, J.L., Wei, L.H., Overexpression of the insulin receptor isoform a promotes endometrial carcinoma cell growth. PLoS One, 8, 2013, e69001.
118. Wang, Z., Lai, S.T., Xie, L., Zhao, J.D., Ma, N.Y., Zhu, J., Ren, Z.G., Jiang, G.L., Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res. Clin. Pract. 106 (2014), 19–26.
119. Wild, S., Roglic, G., Green, A., Sicree, R., King, H., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004), 1047–1053.
120. Williams, C.C., Singleton, B.A., Llopis, S.D., Skripnikova, E.V., Metformin induces a senescence-associated gene signature in breast cancer cells. J. Health Care Poor Underserved 24:1 Suppl (2013), 93–103.
121. Wu, B., Li, S., Sheng, L., Zhu, J., Gu, L., Shen, H., La, D., Hambly, B.D., Bao, S., Di, W., Metformin inhibits the development and metastasis of ovarian cancer. Oncol. Rep. 28 (2012), 903–908.
122. Wullschleger, S., Loewith, R., Hall, M.N., Tor signaling in growth and metabolism. Cell 124 (2006), 471–484.
123. Xie, Y., Wang, Y., Tu, L., Hu, Q., Ji, L., Zhang, Y., Liao, Q.P., Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J. Steroid Biochem. Mol. Biol. 5 (2011), 113–120.
124. Xie, Y., Wang, J.L., Ji, M., Yuan, Z.F., Peng, Z., Zhang, Y., Wen, J.G., Shi, H.R., Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cells. Oncol. Lett. 8 (2014), 1993–1999.
125. Yasmeen, A., Beauchamp, M.C., Piura, E., Segal, E., Pollak, M., Gotlieb, W.H., Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol. Oncol. 121 (2011), 492–498.
126. Zakikhani, M., Dowling, R., Fantus, I.G., Sonenberg, N., Pollak, M., Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66 (2006), 10269–10273.
127. Zhai, J., Liu, C.X., Tian, Z.R., Jiang, Q.H., Sun, Y.P., Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome. Biol. Reprod., 87, 2012, 29.
128. Zhang, Z.J., Li, S., The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes. Metab. 16 (2014), 707–710.
129. Zhang, L., Liao, Q., Effects of testosterone and metformin on glucose metabolism in endometrium. Fertil. Steril. 93 (2010), 2295–2298.
130. Zhang, Z.J., Zheng, Z.J., Kan, H., Song, Y., Cui, W., Zhao, G., Kip, K.E., Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 34 (2011), 2323–2328.
131. Zhang, Z., Dong, L., Sui, L., Yang, Y., Liu, X., Yu, Y., Zhu, Y., Feng, Y., Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. Int. J. Gynecol. Cancer 21 (2011), 213–221.
132. Zhang, H., Gao, C., Fang, L., Zhao, H.C., Yao, S.K., Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand. J. Gastroenterol. 48 (2013), 78–87.
133. Zhang, Q., Celestino, J., Schmandt, R., McCampbell, A.S., Urbauer, D.L., Meyer, L.A., Burzawa, J.K., Huang, M., Yates, M.S., Iglesias, D., Broaddus, R.R., Lu, K.H., Chemopreventive effects of metformin on obesity-associated endometrial proliferation. Am. J. Obstet. Gynecol., 209, 2013, 24 e1-24. e12.
134. Zhang, Z.H., Su, P.Y., Hao, J.H., Sun, Y.H., The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies. Int. J. Gynecol. Cancer 23 (2013), 294–303.
135. Zhang, Y., Li, M.X., Wang, H., Zeng, Z., Li, X.M., Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R. Asian Pac. J. Cancer Prev. 16 (2015), 221–225.
136. Zheng, P.S., Iwasaka, T., Yamasaki, F., Ouchida, M., Yokoyama, M., Nakao, Y., Fukuda, K., Matsuyama, T., Sugimori, H., Telomerase activity in gynecologic tumors. Gynecol. Oncol. 64 (1997), 171–175.
137. Zhou, J., Dsupin, B.A., Giudice, L.C., Bondy, C.A., Insulin-like growth factor system gene expression in human endometrium during the menstrual cycle. J. Clin. Endocrinol. Metab. 5 (1994), 1723–1734.
138. Zhou, B.-B.S., Zhang, H., Damelin, M., Geles, K.G., Grindley, J.C., Dirks, P.B., Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 8 (2009), 806–823.
139. Zordoky, B.N., Bark, D., Soltys, C.L., Sung, M.M., Dyck, J.R., The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention. Biochim. Biophys. Acta 1840 (2014), 1943–1957.